Accounts and other information New IFRS accounting standards The following IFRS standard, which is relevant to the Group, has been issued by the International Accounting Standards Board IASB but is not yet effective or has not yet been adopted by the Group.
Unless otherwise listed below, no other standard, amendment or interpretation is likely to have a material effect on the Groups results of operations or financial position.
In November 2009, the IASB issued IFRS 9 Financial Instruments.
This standard species how the Group should classify and measure financial assets.
It requires all financial assets to be either classied on the basis of the entitys business model and the contractual cash ow characteristics of the financial asset or initially measured at fair value.
This standard has not been endorsed by the EU.
No standard or interpretation coming into effect during the year had a significant effect on the reported results or the financial position of the Group.
The significant accounting policies adopted in the preparation of the Groups accounts are explained with the relevant notes to the accounts.
2 Business segment information For management purposes, the Group is organised into business segments according to the nature of its products and has three business segments Orthopaedics, Endoscopy and Advanced Wound Management.
The types of products and services offered by each business segment are: Orthopaedic reconstruction implants include hip, knee and shoulder joints as well as ancillary products such as bone cement and mixing systems used in cemented reconstruction joint surgery.
Orthopaedic trauma xation products consist of internal and external devices and other products, including shoulder xation and orthobiological materials used in the stabilisation of severe fractures and deformity correction procedures.
Clinical therapies products are those that are applied in an orthopaedic ofce or clinic setting and include bone growth stimulation, joint uid therapies and outpatient spine products.
Smith & Nephews Endoscopy business develops and commercialises endoscopic minimally invasive surgery techniques, educational programmes and value-added services for surgeons to treat and repair soft tissue and articulating joints.
The business focuses on the arthroscopy sector of the endoscopy market.
Arthroscopy is the minimally invasive surgery of joints, in particular the knee, shoulder and hip.
Smith & Nephews Advanced Wound Management business offers a range of products from initial wound bed preparation through to full wound closure.
These products are targeted at chronic wounds associated with the older population, such as pressure sores and venous leg ulcers.
There are also products for the treatment of wounds such as burns and invasive surgery that impact the wider population.
Management monitors the operating results of its business segments separately for the purposes of making decisions about resource allocation and performance assessment.
Group nancing including interest receivable and payable and income taxes are managed on a group basis and are not allocated to business segments.
The following tables present revenue, profit, asset and liability information regarding the Groups operating segments.
The share of results of associates is segmentally allocated to Orthopaedics.
2.1 Revenue by business segment and geography Accounting policy Revenue comprises sales of products and services to third parties at amounts invoiced net of trade discounts and rebates, excluding taxes on revenue.
Revenue from the sale of products is recognised upon transfer to the customer of the significant risks and rewards of ownership.
This is generally when goods are delivered to customers.
Sales of inventory located at customer premises and available for customers immediate use are recognised when notication is received that the product has been implanted or used.
Appropriate provisions for returns, trade discounts and rebates are deducted from revenue.
Rebates comprise retrospective volume discounts granted to certain customers on attainment of certain levels of purchases from the Group.
These are accrued over the course of the arrangement based on estimates of the level of business expected and adjusted at the end of the arrangement to reect actual volumes.
Business segment 2010 2009 2011 $ million $ million $ million Revenue by business segment Orthopaedics 2,312 2,195 2,135 Endoscopy 939 855 791 Advanced Wound Management 1,019 912 846 4,270 3,962 3,772 There are no material sales between business segments.
89 Smith & Nephew Annual Report 2011 Accounts and other information Corporate Governance Business Review Strategy, KPIs & Risk management Overview Accounts and other information Notes to the Group accounts continued Geographic 2011 2010 2009 $ million $ million $ million Revenue by geographic market United Kingdom 283 286 291 Continental Europe 1,118 1,032 1,027 United States 1,756 1,707 1,664 Africa, Asia, Australasia and Other America 1,105 940 795 4,270 3,962 3,772 Revenue has been allocated by basis of origin.
No revenue from a single customer is in excess of 10% of the Groups revenue.
2.2 Trading and operating profit by business segment Trading profit is a trend measure which presents the long-term profitability of the Group excluding the impact of specic transactions that management considers affects the Groups short-term profitability.
The Group presents this measure to assist investors in their understanding of trends.
The Group has identied the following items, where material, as those to be excluded from operating profit when arriving at trading profit: acquisition and disposal related items including amortisation of acquisition intangibles and impairments: significant restructuring events: gains and losses arising from legal disputes: and uninsured losses.
Operating profit reconciles to trading profit as follows: 2011 2010 2009 Notes $ million $ million $ million Operating profit 862 920 723 Acquisition related costs 3 26 Restructuring and rationalisation expenses 3 40 15 42 Amortisation of acquisition intangibles and impairments 8 & 9 36 34 66 3 Legal provision 23 Trading profit 961 969 857 Trading profit by business segment Orthopaedics 492 536 508 Endoscopy 222 200 189 Advanced Wound Management 247 233 160 961 969 857 Operating profit by business segment reconciled to attributable profit for the year 415 Orthopaedics 503 410 Endoscopy 215 197 169 Advanced Wound Management 232 220 144 Operating profit 862 920 723 Net interest payable 8 15 40 Other finance costs 6 10 15 Share of results of associates 2 266 Taxation 280 198 Attributable profit for the year 582 615 472 90 Smith & Nephew Annual Report 2011 Accounts and other information 2.3 Assets and liabilities by business segment and geography Business segment 2011 2010 2009 $ million $ million $ million Balance sheet Assets: Orthopaedics 2,550 2,778 2,656 Endoscopy 846 769 705 Advanced Wound Management 819 755 810 Operating assets by business segment 4,215 4,302 4,171 Assets held for sale relating to Orthopaedics business segment 125 Unallocated corporate assets 407 431 394 Total assets 4,747 4,733 4,565 Liabilities: Orthopaedics 398 457 426 Endoscopy 128 124 111 Advanced Wound Management 146 194 169 Operating liabilities by business segment 695 727 731 Liabilities directly associated with assets held for sale relating to Orthopaedics business segment 19 Unallocated corporate liabilities 846 1,233 1,655 Total liabilities 1,560 1,960 2,386 Unallocated corporate assets and liabilities comprise the following: 2011 2010 2009 $ million $ million $ million Deferred tax assets 223 224 202 Cash and bank 184 207 192 Unallocated corporate assets 407 431 394 Long-term borrowings 16 642 1,090 Retirement benefit obligations 287 262 322 Deferred tax liabilities 66 69 31 Bank overdrafts and loans due within one year 306 57 45 Current tax payable 171 203 167 Unallocated corporate liabilities 846 1,233 1,655 2011 2010 2009 $ million $ million $ million Capital expenditure Orthopaedics 241 227 235 Endoscopy 93 58 41 Advanced Wound Management 31 30 63 365 315 339 Capital expenditure segmentally allocated above comprises: 2011 2010 2009 $ million $ million $ million Additions to property, plant and equipment 229 250 216 Additions to intangible assets 92 65 102 Capital expenditure as per cash ow statement 321 315 318 Acquisitions Goodwill 44 3 Acquisitions Intangible assets 12 Acquisitions Property, plant and equipment 6 Capital expenditure 365 315 339 91 Smith & Nephew Annual Report 2011 Accounts and other information Corporate Governance Business Review Strategy, KPIs & Risk management Overview Accounts and other information Notes to the Group accounts continued 2011 2010 2009 $ million $ million $ million Depreciation, amortisation and impairment Orthopaedics 209 195 206 Endoscopy 41 52 50 Advanced Wound Management 38 37 40 297 273 298 Amounts comprise depreciation of property, plant and equipment, amortisation of other intangible assets, impairment of investments and amortisation of acquisition intangibles and impairments as follows: 2011 2010 2009 $ million $ million $ million Impairment of intangibles and goodwill 32 Amortisation of acquisition intangibles 36 34 34 36 34 66 Depreciation of property, plant and equipment 217 203 206 Amortisation of other intangible assets 42 34 26 Impairment of investments 2 2 297 273 298 Impairments of $2m were recognised within operating profit in 2011 and included within the administrative expenses line 2010 $2m, 2009 $32m.
This is segmentally allocated to Orthopaedics 2010 Orthopaedics, 2009 Orthopaedics $19m and Endoscopy $13m.
Geographic 2010 2011 $ million $ million Assets by geographic location United Kingdom 283 301 Continental Europe 837 891 United States 942 920 Africa, Asia, Australasia and Other America 279 221 Non-current operating assets by geographic location 2,319 2,355 United Kingdom 190 176 Continental Europe 569 543 United States 762 873 Africa, Asia, Australasia and Other America 375 355 Current operating assets by geographic location 1,896 1,947 Assets held for sale 125 Unallocated corporate assets see page 91 407 431 Total assets 4,747 4,733 92 Smith & Nephew Annual Report 2011
